PMID- 24740469
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 48
IP  - 7
DP  - 2014 Jul
TI  - 3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress 
      Disorder.
PG  - 908-915
AB  - OBJECTIVE: Review the current literature assessing the role of 
      3,4-methylenedioxymethamphetamine (MDMA) on posttraumatic stress disorder (PTSD). 
      DATA SOURCES: OVID MEDLINE search (1960-February 2014) using the terms MDMA, 
      3,4-methylenedioxymethamphetamine, Molly, and Ecstasy crossed with posttraumatic 
      stress disorder with backwards citation tracking using references from procured 
      articles. STUDY SELECTION AND DATA EXTRACTION: English language studies assessing 
      MDMA in patients with PTSD. DATA SYNTHESIS: Three randomized controlled trials 
      (RCTs) were conducted along with follow-up open-label and extension evaluations. 
      In the 3 RCTs, therapy with MDMA-assisted psychotherapy is promising, with 
      reductions in PTSD rating scale scores (Clinician-Administered PTSD Scale, 
      Severity of Symptoms Scale for PTSD Scale), although 2 of 3 trials did not show 
      significant results, and all three had methodological limitations. The direction 
      of effect for all trials was toward benefit in patients who were refractory to 
      other PTSD therapies; the percentage reductions on rating scores ranged from 23% 
      to 68%; and in 1 trial, the effect was sustained over a long period of time. MDMA 
      ingestion without sustained psychotherapy over a 6- to 8-hour period is unlikely 
      to be beneficial; trying to prolong the duration of effect with supplemental 
      dosing is unlikely to provide additional benefits; and there are adverse effects 
      on blood pressure and heart rate that should be appreciated. These studies used 
      unadulterated MDMA with known and reproducible potency, which may not happen with 
      street purchase of the product. CONCLUSIONS: MDMA-assisted psychotherapy may be 
      an effective therapy in refractory PTSD but needs further evaluation to determine 
      its place in contemporary therapy.
CI  - (c) The Author(s) 2014.
FAU - White, C Michael
AU  - White CM
AD  - University of Connecticut School of Pharmacy, Hartford, CT, USA 
      Charles.white@uconn.edu.
LA  - eng
PT  - Journal Article
DEP - 20140416
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
OTO - NOTNLM
OT  - MDMA
OT  - Molly/Ecstasy
OT  - PTSD
OT  - posttraumatic stress disorder
OT  - psychotherapy
EDAT- 2014/04/18 06:00
MHDA- 2014/04/18 06:00
CRDT- 2014/04/18 06:00
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2014/04/18 06:00 [medline]
AID - 1060028014532236 [pii]
AID - 10.1177/1060028014532236 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2014 Jul;48(7):908-915. doi: 10.1177/1060028014532236. Epub 
      2014 Apr 16.